1. 康哲药业
  2. 康哲药业
  3. 康哲药业


Business Introduction

Pharmaceutical Business

Innovative Research

With more than two decades experience in introduction of and investment in global products, CMS has accumulated extensive overseas channel resources and market reputation, and established a unique and systematic product evaluation system. The Group acquires innovative products and technologies through industrial equity investment in innovative R&D companies or strategic cooperation with leading pharmaceutical companies around the world. The Group has made equity investments in a number of R&D companies from the U.K., France, Switzerland, the U.S., China, etc., and initiated a new model for industrial investment in innovative drugs, achieving combination of complementary advantages and strong alliance to accelerate the R&D and commercialization progress of innovative products. As at 30 April 2021, the Group has more than 20 innovative products with relatively high innovation level, good market potential and competitive differentiation advantages; among them, 9 innovative products are approved for marketing in the U.S. and/or Europe, and the China’s registration clinical trials of 3 innovative products are completed or underway.



Partners of Existing Products

CMS has created professional brand image and good sales records for a number of quality branded drugs in China, and received the high recognition from dozens of partners of existing products.


Innovative Research

CMS concentrates on innovative products that are global first-in-class or with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems, and has established an innovative pipeline with relatively high innovation level, good market potential and competitive differentiation advantages.


Dermatology & Medical Aesthetics

CMS has been deeply engaged in the field of skin health for many years, and has deployed a number of dermatology products with competitive differentiation advantages, such as Hirudoid (existing exclusive product), Tildrakizumab (innovative drug at the registration trial stage in China); meanwhile, the Group has accumulated abundant sales and promotion resources in the dermatology field. As at 31 December 2020, the Group's sales and promotion network has covered about 57,000 hospitals and medical institutions, over 200,000 retail pharmacies, and about 12,000 dermatologists, and has approximately 700 professional dermatology promotion staff. In order to effectively utilize the sales and promotion channel resources and improve the efficiency in the dermatology field, the Group acquired Luqa Ventures (Luqa), a dermatology specialty company, on 1 February 2021, which has enriched the Group’s dermatology line and expanded the Group’s business boundary with its strengths to enter the medical aesthetic field.



Capitalizing on its strengths such as overseas channel resources accumulated for more than two decades, good reputation, unique product evaluation system, responsive global supply chain system, and strong promotion network, CMS stringently selects functional quality healthcare products with unique ingredients globally according to medical concept and high standards, and supplies the products to Mainland China through cross-border e-commerce platforms, so as to provide consumers with healthy lives.


Investor Relations

Announcements & Circulars

  • 2021-08-02
    Voluntary and Business Update Announcement Methylthioninium Chloride Enteric-coated Sustained-release Tablets Granted an Approval for Drug Clinical Trial
  • 2021-07-21
    Voluntary and Business Update Announcement Positive Results for Tildrakizumab Phase Ⅲ Clinical Trial in China
  • 2021-07-05
    Voluntary and Business Update Announcement New Drug Application of Diazepam Nasal Spray Accepted in China
  • 2021-07-02
    Monthly Return of Equity Issuer on Movements in Securities
  • 2021-06-10
  • 2021-06-02
    Monthly Return of Equity Issuer on Movements in Securities
  • More>>

    Financial Reports

  • Annual Report 2020

  • Interim Report 2020

  • Annual Report 2019

  • Interim Report 2019

  • Annual Report 2018

  • Interim Report 2018

  • More>>

    Stock Quotes